Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 3Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 28Cyclophosphamide 14Nivolumab 13Paclitaxel 7fludarabine 6Specimen Handling 5aldesleukin 4Taxes 4Ipilimumab 4Interleukin-2 4Gemcitabine 4Drug Therapy 4Docetaxel 4Carboplatin 4Bevacizumab 4poly ICLC 3liposomal doxorubicin 3epacadostat 3cobimetinib 3cemiplimab 3Magnetic Resonance Spectroscopy 3Injections 3Cisplatin 3veliparib 2ulixertinib 2sargramostim 2pertuzumab 2pegilodecakin 2pazopanib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × pexidartinib × Dermatologic × Clear all
NCT02452424 2020-03-05

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Daiichi Sankyo

Phase 1/2 Terminated
78 enrolled 19 charts
DermatologicGastrointestinalGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡